vs
Amneal Pharmaceuticals, Inc.（AMRX）与ADVANCED DRAINAGE SYSTEMS, INC.（WMS）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是ADVANCED DRAINAGE SYSTEMS, INC.的1.2倍（$814.3M vs $693.4M），ADVANCED DRAINAGE SYSTEMS, INC.净利率更高（13.5% vs 4.3%，领先9.2%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs 0.4%），ADVANCED DRAINAGE SYSTEMS, INC.自由现金流更多（$183.6M vs $108.5M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 3.0%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Advanced Drainage Systems（简称ADS）是一家美国企业，主营聚丙烯、聚乙烯管材，塑料渗滤场系统、化粪池及配套配件、雨水调蓄设施、PVC排水构件、管件、水过滤与分离设备的设计、生产及销售，是美国规模最大的高密度聚乙烯管道生产商，总部位于俄亥俄州希利厄德。
AMRX vs WMS — 直观对比
营收规模更大
AMRX
是对方的1.2倍
$693.4M
营收增速更快
AMRX
高出11.1%
0.4%
净利率更高
WMS
高出9.2%
4.3%
自由现金流更多
WMS
多$75.0M
$108.5M
两年增速更快
AMRX
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $693.4M |
| 净利润 | $35.1M | $93.6M |
| 毛利率 | 36.5% | 37.4% |
| 营业利润率 | 13.8% | 19.7% |
| 净利率 | 4.3% | 13.5% |
| 营收同比 | 11.5% | 0.4% |
| 净利润同比 | 212.9% | 15.3% |
| 每股收益（稀释后） | $0.10 | $1.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXWMS
| Q4 25 | $814.3M | $693.4M | ||
| Q3 25 | $784.5M | $850.4M | ||
| Q2 25 | $724.5M | $829.9M | ||
| Q1 25 | $695.4M | $615.8M | ||
| Q4 24 | $730.5M | $690.5M | ||
| Q3 24 | $702.5M | $782.6M | ||
| Q2 24 | $701.8M | $815.3M | ||
| Q1 24 | $659.2M | $653.8M |
净利润AMRXWMS
| Q4 25 | $35.1M | $93.6M | ||
| Q3 25 | $2.4M | $156.0M | ||
| Q2 25 | $22.4M | $143.9M | ||
| Q1 25 | $12.2M | $77.2M | ||
| Q4 24 | $-31.1M | $81.2M | ||
| Q3 24 | $-156.0K | $130.4M | ||
| Q2 24 | $6.0M | $161.4M | ||
| Q1 24 | $-91.6M | $94.8M |
毛利率AMRXWMS
| Q4 25 | 36.5% | 37.4% | ||
| Q3 25 | 34.9% | 40.0% | ||
| Q2 25 | 39.5% | 39.8% | ||
| Q1 25 | 36.8% | 36.7% | ||
| Q4 24 | 36.0% | 35.0% | ||
| Q3 24 | 38.4% | 37.6% | ||
| Q2 24 | 35.6% | 40.8% | ||
| Q1 24 | 36.1% | 38.5% |
营业利润率AMRXWMS
| Q4 25 | 13.8% | 19.7% | ||
| Q3 25 | 9.0% | 26.3% | ||
| Q2 25 | 15.4% | 24.8% | ||
| Q1 25 | 14.4% | 19.0% | ||
| Q4 24 | 10.4% | 18.4% | ||
| Q3 24 | 12.6% | 23.9% | ||
| Q2 24 | 13.6% | 27.7% | ||
| Q1 24 | -1.6% | 20.7% |
净利率AMRXWMS
| Q4 25 | 4.3% | 13.5% | ||
| Q3 25 | 0.3% | 18.3% | ||
| Q2 25 | 3.1% | 17.3% | ||
| Q1 25 | 1.8% | 12.5% | ||
| Q4 24 | -4.3% | 11.8% | ||
| Q3 24 | -0.0% | 16.7% | ||
| Q2 24 | 0.9% | 19.8% | ||
| Q1 24 | -13.9% | 14.5% |
每股收益（稀释后）AMRXWMS
| Q4 25 | $0.10 | $1.19 | ||
| Q3 25 | $0.01 | $1.99 | ||
| Q2 25 | $0.07 | $1.84 | ||
| Q1 25 | $0.04 | $0.99 | ||
| Q4 24 | $-0.10 | $1.04 | ||
| Q3 24 | $0.00 | $1.67 | ||
| Q2 24 | $0.02 | $2.06 | ||
| Q1 24 | $-0.30 | $1.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $1.0B |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $1.9B |
| 总资产 | $3.7B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXWMS
| Q4 25 | $282.0M | $1.0B | ||
| Q3 25 | $201.2M | $812.9M | ||
| Q2 25 | $71.5M | $638.3M | ||
| Q1 25 | $59.2M | $463.3M | ||
| Q4 24 | $110.6M | $488.9M | ||
| Q3 24 | $74.0M | $613.0M | ||
| Q2 24 | $43.8M | $541.6M | ||
| Q1 24 | $46.5M | $490.2M |
总债务AMRXWMS
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | $1.3B | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | $1.3B |
股东权益AMRXWMS
| Q4 25 | $-70.8M | $1.9B | ||
| Q3 25 | $-109.5M | $1.8B | ||
| Q2 25 | $-112.1M | $1.7B | ||
| Q1 25 | $-131.7M | $1.5B | ||
| Q4 24 | $-109.3M | $1.5B | ||
| Q3 24 | $-93.4M | $1.4B | ||
| Q2 24 | $-57.5M | $1.3B | ||
| Q1 24 | $-63.7M | $1.2B |
总资产AMRXWMS
| Q4 25 | $3.7B | $4.1B | ||
| Q3 25 | $3.6B | $4.1B | ||
| Q2 25 | $3.4B | $3.9B | ||
| Q1 25 | $3.4B | $3.7B | ||
| Q4 24 | $3.5B | $3.6B | ||
| Q3 24 | $3.5B | $3.5B | ||
| Q2 24 | $3.5B | $3.4B | ||
| Q1 24 | $3.5B | $3.3B |
负债/权益比AMRXWMS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.83× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $269.3M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $183.6M |
| 自由现金流率自由现金流/营收 | 13.3% | 26.5% |
| 资本支出强度资本支出/营收 | 2.7% | 12.4% |
| 现金转化率经营现金流/净利润 | 3.72× | 2.88× |
| 过去12个月自由现金流最近4个季度 | $269.9M | $577.1M |
8季度趋势，按日历期对齐
经营现金流AMRXWMS
| Q4 25 | $130.3M | $269.3M | ||
| Q3 25 | $118.5M | $234.9M | ||
| Q2 25 | $83.8M | $275.0M | ||
| Q1 25 | $7.4M | $41.2M | ||
| Q4 24 | $118.1M | $189.9M | ||
| Q3 24 | $141.8M | $166.9M | ||
| Q2 24 | $39.7M | $183.4M | ||
| Q1 24 | $-4.4M | $17.7M |
自由现金流AMRXWMS
| Q4 25 | $108.5M | $183.6M | ||
| Q3 25 | $106.2M | $176.4M | ||
| Q2 25 | $61.0M | $222.4M | ||
| Q1 25 | $-5.8M | $-5.3M | ||
| Q4 24 | $102.9M | $135.7M | ||
| Q3 24 | $124.8M | $112.4M | ||
| Q2 24 | $29.0M | $125.7M | ||
| Q1 24 | $-13.6M | $-29.8M |
自由现金流率AMRXWMS
| Q4 25 | 13.3% | 26.5% | ||
| Q3 25 | 13.5% | 20.7% | ||
| Q2 25 | 8.4% | 26.8% | ||
| Q1 25 | -0.8% | -0.9% | ||
| Q4 24 | 14.1% | 19.7% | ||
| Q3 24 | 17.8% | 14.4% | ||
| Q2 24 | 4.1% | 15.4% | ||
| Q1 24 | -2.1% | -4.6% |
资本支出强度AMRXWMS
| Q4 25 | 2.7% | 12.4% | ||
| Q3 25 | 1.6% | 6.9% | ||
| Q2 25 | 3.2% | 6.3% | ||
| Q1 25 | 1.9% | 7.6% | ||
| Q4 24 | 2.1% | 7.9% | ||
| Q3 24 | 2.4% | 7.0% | ||
| Q2 24 | 1.5% | 7.1% | ||
| Q1 24 | 1.4% | 7.3% |
现金转化率AMRXWMS
| Q4 25 | 3.72× | 2.88× | ||
| Q3 25 | 50.00× | 1.51× | ||
| Q2 25 | 3.74× | 1.91× | ||
| Q1 25 | 0.61× | 0.53× | ||
| Q4 24 | — | 2.34× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | 6.62× | 1.14× | ||
| Q1 24 | — | 0.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
WMS
| Reportable Segment Aggregation Before Other Operating Segment | $557.3M | 80% |
| Other | $85.5M | 12% |
| Pipe | $35.5M | 5% |
| Allied Products And Other | $15.0M | 2% |
